Liposome-A Comprehensive Approach for Researchers

Sharma, Moni; Joshi, Jyoti; Chouhan, Neeraj Kumar; Talati, Mamta N.; Vaidya, Sandeep; Kumar, Abhiram

doi:10.5772/intechopen.93256

Cited by 9 publications

(3 citation statements)

References 6 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1C). 51,52 This process is advantageous compared to other compressed uidbased methods, as it works under a reduced pressure and at a temperature of around 30 °C. Using this process, various drugs and peptides have been efficiently loaded into nanovesicles.…”

Section: Formulation Methods Of Lipid Nanovesiclesmentioning

confidence: 99%

Strategies for targeted gene delivery using lipid nanoparticles and cell-derived nanovesicles

et al. 2023

View full text Add to dashboard Cite

show abstract

Section: Formulation Methods Of Lipid Nanovesiclesmentioning

confidence: 99%

Strategies for targeted gene delivery using lipid nanoparticles and cell-derived nanovesicles

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Using a mini extrusion kit, a membrane with a pore size of 100-500 nm will be applied such that LUVs may be formed. Liposomes will then be passed through a highpressure extruder for 10 cycles to obtain uniformly structured liposomes [26].…”

Section: Extrusionmentioning

confidence: 99%

The Use of Mannose-Grafted and Lipopetide-Conjugated PE Liposomes in the Delivery of Docetaxel for the Treatment of Glioblastoma Multiforme: A Research Protocol

Gupta¹,

Krishnan²

2022

URNCST Journal

View full text Add to dashboard Cite

Introduction: One of the biggest obstacles in delivering anti-cancer drugs to brain tumours is the penetration of the blood-brain barrier. Docetaxel is a promising drug used for glioblastoma multiforme that works by promoting mitotic arrest and cell death of tumorous cells, yet it encounters this obstacle presented by the selectivity of the blood-brain barrier. Due to the barrier's highly selective nature and the imprecision of current cancer treatments, the use of nanoparticles in drug delivery has been an area of significant interest. To address these issues, we propose using mannose and lipopeptide-grafted phosphatidylethanolamine liposomes as a drug delivery mechanism to effectively eliminate the obstacle of penetrating the blood-brain barrier in the treatment of glioblastomas. The truncated fibroblast growth factor and GALA lipopeptides increase the precision of the chemotherapeutic agent in targeting the tumour cells. Simultaneously, the mannose allows the nanoparticle to be recognized by sugar receptors on the blood-brain barrier, enabling it to pass through. This novel drug delivery system broadens the variety and increases the effectiveness of anti-tumoral drugs used in the treatment of brain cancer. Methods: The lipopeptides are prepared through pyridyl disulfide reactions. The phosphatidylethanolamine liposomes are prepared using standard thin-film hydration in which the lipopeptides, docetaxel, and calcein (to track the drug delivery) are incorporated into the liposomal lumen. Mannose is then grafted onto the liposomal surfaces through the covalent coupling of p-aminophenyl-D-glycosides to phosphatidylethanolamine liposomes. The synthesized liposomes would be administered intravenously alongside radiation. Statistical analyses will be conducted to measure the growth of the tumour and the accuracy of drug delivery. Discussion: The tumour cells should display a greater level of fluorescence, indicating a more accurate administration of the drug. It is expected that the patients will respond favourably to the treatment with the tumorous tissues showing a reduced growth rate and greater bioavailability of the drug. Conclusion:The liposomal drug delivery mechanism presents a novel method by which anti-tumoral drugs can both cross the blood-brain barrier and precisely target the tumorous mass, thereby reducing the risk of drugs getting lost within the vasculature and expanding the horizons for brain tumour prognoses.

show abstract

“…Glucoconjugates can suppress the expression of the efflux pump and thus can synergize the effect of current therapy. Another characteristic feature of glucolipids is that they can be utilized to make formulations like liposomes as they possess self‐aggregation properties, for targeted drug delivery (Corti et al, 2007; Sharma et al, 2020). In our present work, we have synthesized a library of glucoconjugates, particularly glucolipids with varied aliphatic chain lengths and were evaluated them for in vitro studies and selected compound was investigated for in vivo anti‐cancer activities.…”

Section: Introductionmentioning

confidence: 99%

Glucosyltriazole amphiphile treatment attenuates breast cancer by modulating the AMPK signaling

Chouhan,

Eedara,

Talati

et al. 2024

Drug Development Research

View full text Add to dashboard Cite

Breast cancer is the second most frequent cancer among women. Out of various subtypes, triple‐negative breast cancers (TNBCs) account for 15% of breast cancers and exhibit more aggressive characteristics as well as a worse prognosis due to their proclivity for metastatic progression and limited therapeutic strategies. It has been demonstrated that AMP‐activated protein kinase (AMPK) has context‐specific protumorigenic implications in breast cancer cells. A set of glucosyltriazole amphiphiles, consisting of acetylated (9a‐h) and unmodified sugar hydroxyl groups (10a‐h), were synthesized and subjected to in vitro biological evaluation. Among them, 9h exhibited significant anticancer activity against MDA‐MB‐231, MCF‐7, and 4T1 cell lines with IC50 values of 12.5, 15, and 12.55 μM, respectively. Further, compound 9h was evaluated for apoptosis and cell cycle analysis in in vitro models (using breast cancer cells) and antitumour activity in an in vivo model (orthotopic mouse model using 4T1 cells). Annexin‐V assay results revealed that treatment with 9h caused 34% and 28% cell death at a concentration of 15 or 7.5 μM, respectively, while cell cycle analysis demonstrated that 9h arrested the cells at the G2/M or G1 phase in MCF‐7, MDA‐MB‐231 and 4T1 cells, respectively. Further, in vivo, investigation showed that compound 9h exhibited equipotent as doxorubicin at 7.5 mg/kg, and superior efficacy than doxorubicin at 15 mg/kg. The mechanistic approach revealed that 9h showed potent anticancer activity in an in vivo orthotopic model (4T1 cells) partly by suppressing the AMPK activation. Therefore, modulating the AMPK activation could be a probable approach for targeting breast cancer and mitigating cancer progression.

show abstract

Liposome-A Comprehensive Approach for Researchers

Cited by 9 publications

References 6 publications

Strategies for targeted gene delivery using lipid nanoparticles and cell-derived nanovesicles

Strategies for targeted gene delivery using lipid nanoparticles and cell-derived nanovesicles

The Use of Mannose-Grafted and Lipopetide-Conjugated PE Liposomes in the Delivery of Docetaxel for the Treatment of Glioblastoma Multiforme: A Research Protocol

Glucosyltriazole amphiphile treatment attenuates breast cancer by modulating the AMPK signaling

Contact Info

Product

Resources

About